Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1494

Sort by

Sort Order Select

Journal Articles

Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein

Blood (2021) 138 (14): 1269–1277.

https://doi.org/10.1182/blood.2021012938

Published: 2021

Includes: Supplemental data

Journal Articles

Inherited glycosylphosphatidylinositol defects cause the rare Emm-negative blood phenotype and developmental disorders

Blood (2021) 137 (26): 3660–3669.

https://doi.org/10.1182/blood.2020009810

Published: 2021

Includes: Supplemental data

Journal Articles

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Alexandre Slater, Ying Di, Joanne C. Clark, Natalie J. Jooss, Eleyna M. Martin, Fawaz Alenazy, Mark R. Thomas, Robert A. S. Ariëns, Andrew B. Herr, Natalie S. Poulter, Jonas Emsley, Steve P. Watson

Blood (2021) 137 (24): 3443–3453.

https://doi.org/10.1182/blood.2020009440

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

FV/FVa revealed

Josefin Ahnström

Blood (2021) 137 (22): 3011–3013.

https://doi.org/10.1182/blood.2021011573

Published: 2021

Journal Articles

Cryo-EM structures of human coagulation factors V and Va

Eliza A. Ruben, Michael J. Rau, James A. J. Fitzpatrick, Enrico Di Cera

Blood (2021) 137 (22): 3137–3144.

https://doi.org/10.1182/blood.2021010684

Published: 2021

Includes: Supplemental data

Journal Articles

Structure of blood coagulation factor VIII in complex with an anti–C1 domain pathogenic antibody inhibitor

Joseph S. Gish, Lexi Jarvis, Kenneth C. Childers, Shaun C. Peters, Connor S. Garrels, Ian W. Smith, H. Trent Spencer, Christopher B. Doering, Pete Lollar, P. Clint Spiegel, Jr

Blood (2021) 137 (21): 2981–2986.

https://doi.org/10.1182/blood.2020008940

Published: 2021

Includes: Supplemental data

Journal Articles

N-glycan–mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP

Bogac Ercig, Nuno A. G. Graça, Kadri Kangro, Tom Arfman, Kanin Wichapong, Johana Hrdinová, Paul Kaijen, Floris P. J. van Alphen, Maartje van den Biggelaar, Karen Vanhoorelbeke, Agnès Veyradier, Paul Coppo, Chris Reutelingsperger, Gerry A. F. Nicolaes, Andres Männik, Jan Voorberg

Blood (2021) 137 (19): 2694–2698.

https://doi.org/10.1182/blood.2020007972

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates

Gaïa Zirka, Philippe Robert, Julia Tilburg, Victoria Tishkova, Chrissta X. Maracle, Paulette Legendre, Bart J. M. van Vlijmen, Marie-Christine Alessi, Peter J. Lenting, Pierre-Emmanuel Morange, Grace M. Thomas

Blood (2021) 137 (16): 2256–2266.

https://doi.org/10.1182/blood.2020008345

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis

Georg Obermayer, Taras Afonyushkin, Laura Göderle, Florian Puhm, Waltraud Schrottmaier, Soreen Taqi, Michael Schwameis, Cihan Ay, Ingrid Pabinger, Bernd Jilma, Alice Assinger, Nigel Mackman, Christoph J. Binder

Blood (2021) 137 (10): 1406–1415.

https://doi.org/10.1182/blood.2020007155

Published: 2021

Includes: Supplemental data

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

Bioengineered iPSC-derived megakaryocytes for the detection of platelet-specific patient alloantibodies

Nanyan Zhang, Sentot Santoso, Richard H. Aster, Brian R. Curtis, Peter J. Newman

Blood (2019) 134 (22): e1–e8.

https://doi.org/10.1182/blood.2019002225

Published: 2019

Includes: Supplemental data

Journal Articles

The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies

Peter Jandus, Kayluz Frias Boligan, David F. Smith, Elisabeth de Graauw, Bodo Grimbacher, Camilla Jandus, Mai M. Abdelhafez, Alain Despont, Nicolai Bovin, Dagmar Simon, Robert Rieben, Hans-Uwe Simon, Richard D. Cummings, Stephan von Gunten

Blood (2019) 134 (22): 1941–1950.

https://doi.org/10.1182/blood.2019001705

Published: 2019

Includes: Supplemental data

Journal Articles

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

Can Li, MD, Reinaldo Franqui-Machin, Jiliang Xia, PhD, Gregory S. Thomas, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Fangping Chen, MD PhD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 854.

https://doi.org/10.1182/blood-2019-123818

Published: 2019

Journal Articles

Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics

Jason G Underwood, PhD BA, Jenny L. Smith, MSc, MD, Lindsey F. Call, B.A., Elizabeth Tseng, PhD, Tiffany A. Hylkema, BS, Rhonda E. Ries, MA, Amanda R. Leonti, MS, Jason E. Farrar, MD, Timothy Junius Triche, Jr., PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 4658.

https://doi.org/10.1182/blood-2019-131508

Published: 2019

Journal Articles

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

Eftathios Kastritis, Monique C. Minnema, Meletios A. Dimopoulos, MD, Giampaolo Merlini, MD, Pieter Sonneveld, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1868.

https://doi.org/10.1182/blood-2019-126524

Published: 2019

Journal Articles

Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

Maria Karvouni, MSc, PharmD, Heyue Zhou, Arnika Kathleen Wagner, PhD, Qiangzhong Ma, Alamdar H. Baloch, PhD, Tong Zhu, Hong Zhang, Mari Gilljam, Andreas Lundqvist, PhD, Gunnar F. Kaufmann, PhD, Evren Alici, MD PhD

Blood (2019) 134 (Supplement_1): 1848.

https://doi.org/10.1182/blood-2019-127893

Published: 2019

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma

Hiroyuki Takamatsu, MD PhD, Takeshi Yoroidaka, MD, Takeshi Yamashita, MD, Ryoichi Murata, MD, Mikio Ueda, MD PhD, Shinji Nakao, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 3083.

https://doi.org/10.1182/blood-2019-122398

Published: 2019

Journal Articles

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Pallawi Torka, MD, Nishitha Reddy, MD, Adrienne Groman, MS, Angela Kader, Jenna Nichols, Alan Hutson, Cory Mavis, MSc, Joseph Dennis Tario, PhD, Paul K. Wallace, MS, PhD, AnneMarie W. Block, PhD, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Vishala T. Neppalli, MD, Suchitra Sundaram, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 2817.

https://doi.org/10.1182/blood-2019-123488

Published: 2019

Journal Articles

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Tiziana Vaisitti, PhD, Katti Jessen, PhD, Thanh-Trang Vo, PhD, Mira Ko, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Esteban Braggio, PhD, Arianna Di Napoli, Amy Chadburn, MD, John N. Allan, MD, Richard R. Furman, MD, Langdon L. Miller, Brian J Lanutti, PhD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 2856.

https://doi.org/10.1182/blood-2019-126827

Published: 2019

NARROW

Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein

Inherited glycosylphosphatidylinositol defects cause the rare Emm-negative blood phenotype and developmental disorders

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

FV/FVa revealed

Cryo-EM structures of human coagulation factors V and Va

Structure of blood coagulation factor VIII in complex with an anti–C1 domain pathogenic antibody inhibitor

N-glycan–mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP

Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates

Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis

A complementary new drug for PNH

Bioengineered iPSC-derived megakaryocytes for the detection of platelet-specific patient alloantibodies

The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only